Diagnosis and therapy of early neoplasia in Barrett's esophagus

Current Opinion in Gastroenterology

Volumn 21, Issue 4, 2005, Pages 466-471

  Bergman, Jacques J G H M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Autofluorescence endoscopy; Barrett's esophagus; Early cancer; Endoscopic mucosal resection; High grade intraepithelial neoplasia; High resolution endoscopy; Narrow band imaging; Photodynamic therapy

Indexed keywords

BARRETT ESOPHAGUS; CANCER GRADING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DYSPLASIA; ENDOSCOPIC SURGERY; EPITHELIUM TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL ENDOSCOPY; HUMAN; PHOTODYNAMIC THERAPY; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

BARRETT ESOPHAGUS; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; PHOTOCHEMOTHERAPY; TREATMENT OUTCOME;

EID: 21844445094     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003; 98:1931-1939.
2. Falk GW, Skacel M, Gramlich TL, et al. Fluorescence in situ hybridization of cytologic specimens from Barrett's esophagus: a pilot feasibility study. Gastrointest Endosc 2004; 60:280-284. This feasibility study on the use of trans-endoscopic brushing of Barrett's esophagus patients shows that specific chromosomal abnormalities were present in cancer and absent in non-dysplastic patients.
3. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett's esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138:176-186.
4. Endo T, Awakawa T, Takahashi H, et al. Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc 2002; 55:641-647.
5. Guelrud M, Herrera I, Essenfeld H, et al. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 2001; 53:559-565.
6. Guelrud M, Ehrlich EE. Endoscopic classification of Barrett's esophagus. Gastrointest Endosc 2004; 59:58-65.
7. Sharma P, Weston AP, Topalovski M, et al. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut 2003; 52:24-27.
8. Sharma P, Dixon A, Weston AP. Correlation between gastric histology and Narrow Band Imaging, a novel endoscopic imaging technique. Gastroenterology 2003; 124(4 suppl 1):A-49.
9. Kara MA, Ennahachi M, Fockens P, et al. What features Are Relevant for the Detection of High-grade Dysplasia (HGD) and Early Cancer (EC) using Narrow-Band Imaging? Gastroenterology 2004; 126:A50.
10. Haringsma J, Tytgat GN, Yano H, et al. Autofluorescence endoscopy: feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology. Gastrointest Endosc 2001; 53:642-650.
11. Niepsuj K, Niepsuj G, Cebula W, et al. Autofluorescence endoscopy for detection of high-grade dysplasia in short-segment Barrett's esophagus. Gastrointest Endosc 2003; 58:715-719.
12. Bergman JJ, Kara MA, Smits ME, et al. A Randomised Cross-over Study Comparing Light-Induced Fluorescence Endoscopy (LIFE) with Standard Endoscopy (SE) for detection of early neoplasia in Barrett's Esophagus (BE). Gastrointest Endosc 2005. (In press)
13. Egger K, Werner M, Meining A, et al. Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut 2003; 52:18-23.
14. Kara MA, Peters FP, Fockens P, et al. The First Experience with Video Autofluorescence Endoscopy for Detection of High-grade Dysplasia and Early Cancer in Barrett's Esophagus. Gastrointest Endosc 2005. (In press)
15. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118:670-677.
16. May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 14:1085-1091.
17. Vieth M, Ell C, Gossner L, et al. Histological analysis of endoscopic resection specimens from 326 patients with Barrett's esophagus and early neoplasia. Endoscopy 2004; 36:776-781. This is the largest series on pathology of EMR specimens published by a respected group of pathologists.
18. Buskens CJ, Westerterp M, Lagarde SM, et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004; 60:703-710. Barrett's esophagus patients with mucosal cancers as well as those with superficial submucosal infiltration (sm1) had a very low chance of local lymph node involvement (0/51) versus 23% and 69% for patients with sm2 and sm3 tumors, respectively.
19. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: Long-term results. Gastrointest Endosc 2003; 58:183-188.
20. Buttar NS, Wang KK, Lutzke LS, et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 2001; 54:682-688.
21. Ackroyd R, Kelty CJ, Brown NJ, et al. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 2003; 35:496-501.
22. Barr H. Barrett's esophagus: treatment with 5-aminolevulinic acid photodynamic therapy. Gastrointest Endosc Clin N Am 2000; 10:421-437.
23. Gossner L, May A, Sroka R, et al. Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5-aminolevulinic acid. Cancer 1999; 86:1921-1928.
24. Barr H, Shepherd NA, Dix A, et al. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348:584-585.
25. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114:448-455.
26. Ackroyd R, Brown NJ, Davis MF, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 2000; 47:612-617.
27. Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic resection combined with Photodynamic Therapy for high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc 2004. (in press)
28. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000; 46:574-577.
29. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58:183-188.
30. Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000; 119:624-630.
31. Hage M, van Dekken H, Vissers KJ, et al. Molecular aberrations are still present after ablative therapy of Barrett's esophagus. Gastrointest Endosc 2004; 59:AB249. ([abstract])
32. Chen X, Ding YW, Yang G, et al. Oxidative damage in an esophageal adenocarcinoma model with rats. Carcinogenesis 2000; 21:257-263.
33. Farhadi A, Fields J, Banan A, et al. Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression toward esophageal cancer? Am J Gastroenterol 2002; 97:22-26.
34. Olyaee M, Sontag S, Salman W, et al. Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus. Gut 1995; 37:168-173.
35. Wetscher GJ, Hinder RA, Klingler P, et al. Reflux esophagitis in humans is a free radical event. Dis Esophagus 1997; 10:29-32.
36. Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000; 119:624-630.
37. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58:183-188.
38. Wang KK, Buttar NS, Wong Kee Song LM, et al. Assessment of genetic defects in patients with complete versus partial ablation after photodynamic therapy (PDT) for Barrett's esophagus. Gastroenterology 2004; 126(4 suppl 2):A-177. (abstract)
39. Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003; 57:854-859.
40. Giovannini M, Bories E, Pesenti C, et al. Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy 2004; 36:782-787. This is an excellent retrospective cohort study, though results may be underestimated because the authors did not ablate small residual islands after EMR.
41. Miyamoto S, Muto M, Hamamoto Y, et al. A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointest Endosc 2002; 55:576-581.
42. Rajan E, Gostout CJ, Feitoza AB, et al. Widespread EMR: a new technique for removal of large areas of mucosa. Gastrointest Endosc 2004; 60:623-627. This is a feasibility study on the use of a prototype EMR-cap in pigs allowing semicircumferential EMR. Resection of the contralateral side at a second endoscopy proved to be difficult and dangerous.